Andrew Bowser
Ocular comorbidities associated with atopic dermatitis
Ocular comorbidity risk is already high in patients with atopic dermatitis and may increase even further as biologic agents are introduced, a study shows.
Atopic dermatitis and psoriasis as a spectrum condition
Thinking of psoriasis and atopic dermatitis as a spectrum, rather than separate diseases might lead to better understanding, and potentially better treatments.
Atopic Dermatitis in 2018
Until recently, atopic dermatitis treatments were primarily limited to topical corticosteroids and systemic immunosuppressants. Now, two new therapies have reached clinical practice. Nineteen more are in development.
In atopic dermatitis, are you employing the therapeutic ladder approach?
Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.
Atopic dermatitis: Biologics to watch in 2018
In this article, we take a look at the development of new treatments for atopic dermatitis.
Recruitment underway for atopic dermatitis serlopitant trial
Early trial results show a significant reduction of itch with the oral NK-1 antagonist serlopitant
When other treatments fail in atopic dermatitis, dupilumab succeeds
Dupilumab plus topical corticosteroids safe and effective after failure of cyclosporine in moderate-to-severe atopic dermatitis
Secukinumab safe and effective through 5 years in psoriasis
Patients were continually treated with the 300 mg for five years.
Cutaneous side effects of melanoma drugs
Dermatologists need “hands on” experience, researchers say at EADV 2017.
Update: Immunotherapeutic options in advanced melanoma
At EADV, Dr. Simone Ribero reviews the latest data on new treatments for advanced melanoma.

Poll

View Results